News
-
-
-
COMMUNIQUÉ DE PRESSE
BIOVERSYS ANNOUNCES REPORTING DATE FOR FULL-YEAR 2024 FINANCIAL RESULTS AND EVENT DETAILS
BioVersys AG announces reporting date for full-year 2024 financial results and event details, including a conference call and webcast on March 26, 2025. The company focuses on developing novel antibacterial products for MDR bacteria -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
BIOVERSYS SUCCESSFULLY ADVANCES BV500 NTM PROGRAM WITH CONTINUED SUPPORT FROM CF AMR SYNDICATE
BioVersys advances BV500 NTM program with continued support from CF AMR Syndicate, developing therapies for NTM lung disease in CF patients. Company focuses on antibacterial products against MDR bacteria -